Table 1.

IC₅₀ values (µM) for the inhibition of in‐vitro cell growth of human cancer cell lines by compounds 7–22 a.

Tumor cell line	IC50 (µM)
	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	Cisplatinb
RT‐4	8.5 ± 2.4	22.1 ± 6.4	2.4 ± 0.4	1.9 ± 0.7	1.3 ± 0.26	1.08 ± 0.56	1.68 ± 0.04	1.4 ± 0.18	2.7 ± 0.08	1.45 ± 1.23	2.8 ± 0.37	1.77 ± 0.15	1.19 ± 0.35	3.58± 0.3	1.76 ± 0.08	1.20 ± 0.22	1.61
5637	4.1 ± 0.5	4.2 ± 1.6	12.3 ± 2.56	2.1 ± 0.6	0.96 ± 0.55	0.77 ± 0.6	1.06 ± 0.17	1.3 ± 0.09	3.6 ± 0.33	3.2 ± 0.15	0.89 ± 0.7	1.51 ± 0.69	1.22 ± 0.52	5.27 ±3.00	1.38 ± 0.33	0.84 ± 0.11	0.35
DAN‐G	11.5 ± 2.8	11.2 ± 1.5	1.17 ± 0.14	1.7 ± 0.46	1.1 ± 0.6	0.55 ± 0.25	1.04 ± 0.14	1.7 ± 0.8	3.11 ± 0.4	1.5 ± 0.13	2.49 ± 1.1	1.71± 0.16	0.67 ± 0.11	4.34 ± 0.94	1.43 ± 0.24	0.90 ± 0.13	0.73
LCLC‐103H	6.2 ± 0.4	7.5 ± 1.5	1.4 ± 0.4	0.78 ± 0.16	0.8 ± 0.05	0.49 ± 0.54	0.82 ± 0.02	1.46 ± 0.6	1.65 ± 0.18	1.15 ± 1.3	2.4 ± 0.17	2.64 ± 0.73	1.24 ± 0.34	6.29 ± 1.61	0.95 ± 0.06	0.89 ± 0.08	0.90
A‐427	6.4 ± 0.8	5.5 ± 0.77	3.0 ± 0.47	2.98 ± 0.55	3.0 ± 0.12	6.6 ± 0.22	12.2 ± 5.09	4.4 ± 0.6	5.35 ± 2.68	2.7 ± 0.29	2.3 ± 0.07	2.55 ± 1.33	2.12 ± 0.93	5.32 ± 2.20	4.25 ± 1.82	4.07 ± 1.08	1.96
MCF‐7	18.1 ± 0.58	13.5 ± 0.45	5.7 ± 0.6	2.27 ± 0.97	1.8 ± 0.64	1.06 ± 0.38	1.37 ± 0.2	2.1 ± 0.7	2.66 ± 0.34	1.5 ± 0.08	3.5 ± 0.68	2.03 ± 0.60	0.80 ± 0.27	4.48 ± 1.24	1.60 ± 0.16	0.75 ± 0.07	1.38
Average d	9.15	10.7	4.3	1.97	1.50	1.76	3.02	2.08	3.17	1.93	2.4	2.03	1.20	4.88	1.89	1.44	1.15
RSDe (%)	55	62	98	36	54	136	149	58	39	43	36	23	42	19	62	90	83

^aValues are averages of three independent determinations ± 1 SD.

^bValues were from 21. ^c Nd – not determined.

^dAveraged IC₅₀ values over all tested cancer cell lines.

^eRelative standard deviation.